BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 23455361)

  • 1. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.
    Manes A; Palazzini M; Leci E; Bacchi Reggiani ML; Branzi A; Galiè N
    Eur Heart J; 2014 Mar; 35(11):716-24. PubMed ID: 23455361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 3. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).
    Barst RJ; Ivy DD; Foreman AJ; McGoon MD; Rosenzweig EB
    Am J Cardiol; 2014 Jan; 113(1):147-55. PubMed ID: 24176071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts.
    Vijarnsorn C; Durongpisitkul K; Chungsomprasong P; Bositthipichet D; Ketsara S; Titaram Y; Chanthong P; Kanjanauthai S; Soongswang J
    PLoS One; 2018; 13(4):e0195092. PubMed ID: 29664959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival.
    Sajan I; Manlhiot C; Reyes J; McCrindle BW; Humpl T; Friedberg MK
    Am Heart J; 2011 Sep; 162(3):562-8. PubMed ID: 21884877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
    Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies.
    D'Alto M; Diller GP
    Heart; 2014 Sep; 100(17):1322-8. PubMed ID: 24829371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria.
    Douwes JM; van Loon RL; Hoendermis ES; Vonk-Noordegraaf A; Roofthooft MT; Talsma MD; Hillege HL; Berger RM
    Eur Heart J; 2011 Dec; 32(24):3137-46. PubMed ID: 21893489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
    Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.
    Douwes JM; Roofthooft MT; Bartelds B; Talsma MD; Hillege HL; Berger RM
    Int J Cardiol; 2013 Sep; 168(2):1370-7. PubMed ID: 23340486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value.
    Scognamiglio G; Kempny A; Price LC; Alonso-Gonzalez R; Marino P; Swan L; D' Alto M; Hooper J; Gatzoulis MA; Dimopoulos K; Wort SJ
    Heart; 2014 Sep; 100(17):1335-41. PubMed ID: 24790070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital heart disease-associated pulmonary arterial hypertension: preliminary results from a novel registry.
    Rose ML; Strange G; King I; Arnup S; Vidmar S; O'Donnell C; Kermeen F; Grigg L; Weintraub RG; Celermajer DS
    Intern Med J; 2012 Aug; 42(8):874-9. PubMed ID: 22212153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.
    van Loon RL; Roofthooft MT; Hillege HL; ten Harkel AD; van Osch-Gevers M; Delhaas T; Kapusta L; Strengers JL; Rammeloo L; Clur SA; Mulder BJ; Berger RM
    Circulation; 2011 Oct; 124(16):1755-64. PubMed ID: 21947294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Pulmonary Artery Compliance in Patients with Pulmonary Arterial Hypertension Associated with Adult Congenital Heart Disease.
    Cheng XL; Liu ZH; Gu Q; Ni XH; Luo Q; Zhao ZH; He JG; Xiong CM
    Int Heart J; 2017 Oct; 58(5):731-738. PubMed ID: 28966315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
    Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
    Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M; Romeo E; Argiento P; D'Andrea A; Sarubbi B; Correra A; Scognamiglio G; Papa S; Bossone E; Calabrò R; Vizza CD; Russo MG
    Int J Cardiol; 2013 Apr; 164(3):323-6. PubMed ID: 21802156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.